| Similar Articles |
|---|
 |
The Motley Fool
September 2, 2010
Brian Orelli |
Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.   |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
The Motley Fool
January 5, 2011
Brian Orelli |
Pfizer Goes Back for Seconds Headed back for more from Santaris. The company is putting up just $14 million for expanded access to Santaris' LNA technology. |
The Motley Fool
May 18, 2010
Brian Orelli |
Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping. |
The Motley Fool
December 10, 2010
Brian Orelli |
Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
March 3, 2010
Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool
June 29, 2011
Brian Orelli |
Doubling Up in Biotech Lilly hits multiple targets with one drug. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
The Motley Fool
January 25, 2011
Brian Orelli |
FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares. |
Chemistry World
November 18, 2010
Ned Stafford |
New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system. |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
March 15, 2011
Brian Orelli |
Extending the Competition in Parkinson's Disease Impax's extended-release drug looks good. |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
Chemistry World
April 19, 2011
Simon Hadlington |
Cell factories package drugs for delivery Scientists in Australia and Germany have used living cells as 'factories' to encapsulate particles such as drugs in biological membranes. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
November 30, 2010
Brian Orelli |
RNAi Is On Sale The novel technology looks more promising at these prices. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
February 28, 2011
Brian Orelli |
Look Out for Big Growth From This Drug Regeneron's ultra-orphan drug Arcalyst takes a step forward toward a wider audience. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool
February 10, 2010
Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
The Motley Fool
April 7, 2011
Brian Orelli |
Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market. |
The Motley Fool
August 27, 2009
Brian Orelli |
The List You Have to Be On Good for you if your company's products made the cut in China. This sounds like a growth opportunity for American Oriental Bioengineering and anyone else who can get a place on the list. |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
Chemistry World
April 27, 2011
Carol Stanier |
Drug cocktails greater than the sum of their parts Canadian scientists have shown that combining an antibiotic that is past its prime with other drugs can give it a new lease of life. |
Chemistry World
January 19, 2011
Jon Cartwright |
Modified protein binders give shortcut to drugs The method, which involves attaching polypeptides to the binders, could help reduce the work required to develop protein binders into safer drugs. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
December 29, 2009
Brian Orelli |
Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others. |
The Motley Fool
January 8, 2010
Brian Orelli |
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. |
BusinessWeek
September 23, 2010
Rob Waters |
Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed. |
The Motley Fool
June 6, 2006
Brian Lawler |
Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines. |
Chemistry World
May 26, 2011
Rebecca Brodie |
Nanospray for nanodrugs Teams from the US and Germany have developed a spray drying technique to fabricate drug formulations smaller than 100nm for pharmaceutical trials, improving the drugs' solubility, or bioavailability. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
April 13, 2011
Brian Orelli |
Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients. |
The Motley Fool
December 4, 2006
Michael Leibert |
Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors. |
The Motley Fool
July 29, 2010
Brian Orelli |
Buy, Sell, or Hold: Biotech Generics Generic biotech drugs are coming. Hop on. |
The Motley Fool
September 3, 2010
Brian Orelli |
Why You Just Got Hammered Celldex's decline is due to potential reasons Pfizer would send back a drug it's been working on with Celldex for over two years |
The Motley Fool
September 15, 2010
Brian Orelli |
Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
February 23, 2010
Brian Orelli |
The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston. |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
